CANY
RXST icon

Caxton Associates (New York)’s RxSight RXST Stock Holding History

Caxton Associates (New York)’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,739
Closed -$1.73M – 636
2024
Q2 		$1.73M Buy
28,739
+5,312
+23% +$304K 0.06% 167
2024
Q1 		$1.21M Buy
+23,427
New +$1.15M 0.07% 193

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s RXST Position: Q3 2024 in Review

Caxton Associates (New York) sold out of RxSight (RXST) in Q3 2024, closing a stake of 28,739 shares — an estimated $1.73M sold.

Caxton Associates (New York) first reported a position in RXST in Q1 2024 and held it in 2 quarters. The position peaked at $1.73M in Q2 2024. 214 funds tracked by Wall St. Rank hold RXST as of Q3 2024.

  • Caxton Associates (New York) reported no remaining RxSight position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 28,739 RxSight shares in Q3 2024, an estimated $1.73M.
  • Caxton Associates (New York) first reported a position in RxSight in Q1 2024 and held it in 2 quarters.
  • Caxton Associates (New York)'s RxSight position peaked at $1.73M in Q2 2024.
  • 214 funds tracked by Wall St. Rank held RxSight as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.